ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

HYCAMTIN
Gynecologic cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

HYCAMTIN Rx

Generic Name and Formulations:
Topotecan (as HCl) 4mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains mannitol; preservative-free.

Company:
Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for HYCAMTIN:

Metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. In combination with cisplatin for Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.

Adult:

Verify dose using BSA. Usual max dose 4mg IV. Confirm baseline neutrophils ≥1,500cells/mm3 and platelets ≥100,000cells/mm3 prior to 1st course of therapy. Give by IV infusion over 30mins. Ovarian cancer: 1.5mg/m2 daily for 5 consecutive days, starting on Day 1 of a 21-day cycle; continue until disease progression or unacceptable toxicity. Cervical cancer: 0.75mg/m2 on Days 1 (with cisplatin), 2, and 3 of a 21-day cycle. Renal impairment (CrCl 20–39mL/min): 0.75mg/m2/day. Dose modifications: see full labeling.

Children:

Not established.

Boxed Warning:

Myelosuppression.

Warnings/Precautions:

Monitor peripheral blood cell counts during therapy; hold subsequent doses until neutrophils >1,000cells/mm3, platelets >100,000cells/mm3, and hemoglobin ≥9g/dL. History of interstitial lung disease, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, use of pneumotoxic drugs and/or colony stimulating factors: increased risk of interstitial lung disease; monitor, discontinue if occurs. Moderate-to-severe renal impairment (see Adults). Avoid extravasation. Embryo-fetal toxicity. Use effective contraception during and for 6 months (females) or 3 months (males w. female partners) after last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended.

Pharmacological Class:

Topoisomerase inhibitor.

Interactions:

Myelosuppression potentiated with platinum agents.

Adverse Reactions:

Neutropenia, anemia, thrombocytopenia, febrile neutropenia, nausea, vomiting, fatigue, diarrhea, dyspnea, asthenia, pneumonia, abdominal pain, pain, infection, alopecia, anorexia; interstitial lung disease, neutropenic colitis (may be fatal).

How Supplied:

Single-use vials—1

Indications for HYCAMTIN:

Small cell lung cancer (SCLC) with platinum-sensitive disease that progressed at least 60 days after initiation of 1st line chemotherapy.

Adult:

Verify dose using BSA. Usual max dose 4mg IV. Confirm baseline neutrophils ≥1,500cells/mm3 and platelets ≥100,000cells/mm3 prior to 1st course of therapy. Give by IV infusion over 30mins. 1.5mg/m2 daily for 5 consecutive days, starting on Day 1 of a 21-day cycle. Renal impairment (CrCl 20–39mL/min): 0.75mg/m2/day. Dose modifications: see full labeling.

Children:

Not established.

Boxed Warning:

Myelosuppression.

Warnings/Precautions:

Monitor peripheral blood cell counts during therapy; hold subsequent doses until neutrophils >1,000cells/mm3, platelets >100,000cells/mm3, and hemoglobin ≥9g/dL. History of interstitial lung disease, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, use of pneumotoxic drugs and/or colony stimulating factors: increased risk of interstitial lung disease; monitor, discontinue if occurs. Moderate-to-severe renal impairment (see Adults). Caps: severe diarrhea; may need to reduce dose. IV: avoid extravasation. Embryo-fetal toxicity. Use effective contraception during and for 6 months (females) or 3 months (males w. female partners) after last dose. Pregnancy; exclude status prior to initiation. Nursing mothers: not recommended.

See Also:

HYCAMTIN CAPSULES

Pharmacological Class:

Topoisomerase inhibitor.

Interactions:

IV: myelosuppression potentiated with platinum agents. Caps: potentiated by P-gp (eg, cyclosporine) or BCRP inhibitors; avoid concomitant use.

Adverse Reactions:

Neutropenia, anemia, thrombocytopenia, febrile neutropenia, nausea, vomiting, fatigue, diarrhea, dyspnea, asthenia, pneumonia, abdominal pain, pain, infection, alopecia, anorexia; interstitial lung disease, neutropenic colitis (may be fatal).

How Supplied:

Single-use vials—1; Caps—10

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs